Phesi selected as finalist for 2018 scrip award

Date: 10. 10. 2018

(BUSINESS WIRE) October 10, 2018

EAST LYME, Conn. Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused category, which “recognize[s] the promising and disruptive role that digital health technology now plays in clinical drug development,” according to the Scrip Awards 2018 website.

Read the full press release at Business Wire.

Related news
10. 14. 2022
Phesi launches AI-driven Trial Accelerator™ to enable simulated trials and deliver comprehensive view of the patient throughout clinical development and commercialization Read more
10. 06. 2022
Almost half of Ukraine’s clinical trials to find new therapies are still recruiting patients despite ongoing conflict, Phesi analysis shows Read more
09. 21. 2022
New Phesi Analysis of 117,000 Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants Read more
06. 23. 2022
48% of US cancer clinical trials have no Hispanic or Latin American representation, and 42% do not include a single Black patient, Phesi analysis reveals Read more
06. 01. 2022
Use of digital twins will be essential in accelerating the use of CAR-T in cancer treatment and mitigating the side effects, says Phesi Read more
05. 06. 2022
Phesi global analysis of 2.5 million patients finds participants in breast cancer clinical trials are getting younger Read more